Clinical Trial Update: Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update exploring Sacituzumab Tirumotecan with or without radiotherapy for EGFR-mutant non-small cell lung cancer with brain metastases; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations | Phase 2 | Status: NOT_YET_RECRUITING